PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsEarly clinical success for stem cell gene therapy in two diseases

BioNews

Early clinical success for stem cell gene therapy in two diseases

Published 12 July 2013 posted in News and appears in BioNews 713

Author

Dr Nikki Davis

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

A clinical trial of a gene therapy to treat children with two types of severe genetic disease has shown early signs of success...

A clinical trial of a gene therapy to treat children with two types of severe genetic disorders has shown early signs of success.

'The results obtained from the first six patients are very encouraging', said Professor Luigi Naldini, director of the San Raffaele Telethon Institute for Gene Therapy (TIGET) in Italy, who led the research. 'The therapy is not only safe, but also effective, and able to change the clinical history of these severe diseases'.

Two rare genetic diseases, metachromatic leukodystrophy (MLD) and Wiskott-Aldrich syndrome, were targeted in the trials. The diseases are caused by inherited gene mutations and affect patients in early childhood, with debilitating or even fatal effects.

Researchers used a new, harmless version of the HIV virus to deliver correct copies of the defective gene. They collected bone marrow cells from the patients and used the modified virus to carry the normal gene into those cells. The patient's defective bone marrow was then destroyed, and the modified cells were transplanted back into the patient to replace them.

Sixteen children have been treated in the clinical trials to date but only six children, three with each disease, have been followed for sufficient time to draw initial conclusions. The children with MLD received gene therapy before symptoms appeared and have so far developed no symptoms of the disease. Symptoms usually develop around the age of one. Children with Wiskott-Aldrich syndrome typically have progressively worsening health, but the children involved in the trial showed improvements in their symptoms.

The risk of tumours following gene therapy has been a problem seen when trialling other gene therapy techniques and has hampered progression in this field. However, the children in these trials were followed for up to two and a half years after treatment and have so far shown no signs of cancer.

'Until now we have never seen a way to engineer stem cells using gene therapy that is as effective and safe as this one', said Dr Eugenio Montini of TIGET, and a co-author of the studies. 'These results pave the way for new therapies for other more common diseases'.

MLD causes progressive neurodegeneration, resulting in paralysis and dementia. Few children survive beyond a few years after onset, and there is currently no other effective treatment available. Wiskott-Aldrich syndrome affects the immune system and children are at risk of recurrent infections, autoimmune diseases and cancer. Its progression can be halted by a bone-marrow transplant, if a suitable matched donor can be found, but life expectancy is low at 15-20 years.

'The results we're showing today…give us a great hope for the future of these children', said Professor Maria Grazia Roncarolo, scientific director of the San Raffaele Scientific Institute, who was also involved in the research.

'The field is slowly but surely making impressive advances against…quite untreatable diseases', Dr Theodore Friedmann, a paediatric gene therapist at UC San Diego who was not involved in these studies, told the LA Times.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
1 November 2013 • 2 minutes read

Clinical-stage gene therapy company launched

by Dr Naqash Raja

The Children's Hospital of Philadelphia has invested US $50 million in a biotech start-up in an effort to commercialise gene therapy...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
21 March 2013 • 2 minutes read

Just five patients but gene therapy leukaemia trial yields positive results

by John Brinsley

Early results of an experimental gene therapy against an aggressive form of leukaemia have been hailed by researchers as showing 'life saving potential'....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
31 January 2013 • 3 minutes read

Gene therapy beneficial but not permanent in serious immune disorder

by Ayesha Jadoon

Early trials in patients with chronic granulomatous disorder (x-CGD), a recessive X-linked condition that affects the immune system, have shown signs of success following the use of gene therapy. The observed boost in immunity of those undergoing treatment was only temporary, however, and the faulty gene causing x-CGD was not corrected permanently....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
30 January 2013 • 2 minutes read

Gene therapy successfully treats inherited blindness

by Dr Maria Botcharova

Three women have reported a significant improvement in sight following gene therapy in both their eyes. Initially, they received the therapy in just one eye, but this latest study demonstrates the treatment was also successful in the other...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
2 November 2012 • 2 minutes read

Gene therapy approved in Europe for first time

by Dr Lucy Spain

The European Medicines Agency (EMA) has approved Glybera, a gene therapy to treat a rare genetic condition, lipoprotein lipase deficiency (LPLD), for sale across Europe. Glybera is the first gene therapy to be approved for the Western market and offers the first therapeutic treatment for people with LPLD....

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Update to article: Fertility expert condemns 'outrageous' IVF cell cycle patent

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Common virus may be cause of recent hepatitis cases in children

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

1 August 2022 • 2 minutes read

CRISPR genome editing treatments may raise cancer risk

1 August 2022 • 2 minutes read

Differences in IVF-conceived children's size disappear by adolescence

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856